Ruxolitinib for Vitiligo Approved for Marketing in EU Ruxolitinib for Vitiligo Approved for Marketing in EU

Last year in the United States, the topical JAK inhibitor became the first repigmentation treatment approved by the FDA for nonsegmental vitiligo, the most common form of the disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news